Walsh C
Division of Oncology, Kaplan Cancer Center, New York University.
Oncology (Williston Park). 1989 Oct;3(10):79-83; discussion 84-6.
Treatment results using standard chemotherapeutic regimens for patients with intermediate and high-grade non-Hodgkin's lymphoma have been disappointing. For patients with HIV-associated lymphoma, whose bone marrow tolerance is so limited, conservative dose combination chemotherapy has been the only realistic option. Now, however, the availability of recombinant colony-stimulating factors allows more dose-intensive therapy to be used. Both recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor have undergone Phase I testing and have been shown to reduce bone marrow toxicity following combination chemotherapy in non-HIV-infected patients. While this may be a promising lead for the treatment of HIV-infected patients also, it must be noted that until randomized trials are performed, no clear effects on survival or response can be verified.
对于中高度恶性非霍奇金淋巴瘤患者，采用标准化疗方案的治疗效果一直不尽人意。对于骨髓耐受性非常有限的HIV相关淋巴瘤患者，保守剂量联合化疗一直是唯一现实的选择。然而，现在重组集落刺激因子的出现使得可以采用更强化的剂量治疗。重组人粒细胞集落刺激因子和重组人粒细胞巨噬细胞集落刺激因子均已进行了I期试验，并已证明可降低未感染HIV患者联合化疗后的骨髓毒性。虽然这对于治疗感染HIV的患者可能也是一个有希望的线索，但必须指出，在进行随机试验之前，无法证实对生存率或反应有明确影响。
